
Just under five months after Novo Nordisk secured a US Food and Drug Administration (FDA) approval for sending the once-weekly growth hormone Sogroya on the market the European Medicines Agency (EMA) also announces their positive assessment of the treatment.
At the Committee for Medicinal Products for Human use meeting in January, the group of experts passed an EMA recommendation to issue a marketing authorization for the drug as a treatment for adults.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app